Sign In
Buy HRTX
$0.496
-0.0012 (-0.241%)
At Close: Jul 31, 2026
Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
06:26pm, Wednesday, 01'st Jul 2020
It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the small-cap biotech received another CRL (complete response letter) for its experimental post-opera
2 Biotech Stocks That Could Soar in 2020 | The Motley Fool
11:12am, Wednesday, 01'st Jul 2020
These companies offer promising pipelines that could deliver in the long term.
Heron's Pain Management Drug Gets Complete Response Letter
03:15pm, Tuesday, 30'th Jun 2020
Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.
Heron Therapeutics: The Play Now
01:41pm, Tuesday, 30'th Jun 2020
The stock of Heron Therapeutics sold off hard in trading Monday after receiving an unexpected CRL from the FDA for HTX-011 for post operative pain. However, the
Kiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
01:14pm, Tuesday, 30'th Jun 2020
Kiniksa's heart inflammation drug shows positive results. Heron's HTX-011 gets a CRL. SEGN's Tisotumab Vedotin reports positive data.
Cancer Therapeutics & Supportive Care Drugs Market Research Report by Drug Class (Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents, Granulocyte-Colony Stimulating Factors, and Nonsteroi
Xconomy: FDA Again Dings Heron’s Opioid Alternative Over “Nonclinical Issues”
09:39pm, Monday, 29'th Jun 2020
Heron Therapeutics revealed Monday that its investigational non-opioid drug for treating postoperative pain has again been rejected by the FDA. The San
So far Monday, June 29, NASDAQ is up 3.38% and the S&P is up 2.09%. Let’s take a look at
Why Pacira BioSciences Is Soaring Today | The Motley Fool
04:58pm, Monday, 29'th Jun 2020
Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.
Heron Therapeutics (HRTX) Initiated with a Buy at Stifel Nicolaus - Markets
03:44pm, Monday, 29'th Jun 2020
Stifel Nicolaus analyst Derek Archila initiated coverage with a Buy rating on Heron Therapeutics (HRTX – Research Report) today and
Why Heron Therapeutics Stock Is Tanking Today | The Motley Fool
03:25pm, Monday, 29'th Jun 2020
Its non-opioid painkiller gets a rejection over non-clinical issues.
U.S. FDA again declines to approve Heron Therapeutics' non-opioid painkiller
02:04pm, Monday, 29'th Jun 2020
Heron Therapeutics said on Monday the U.S. Food and Drug Administration has once again declined to approve its non-opioid painkiller for post-operative pain and sought more data, sending its shares do
Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options
12:47pm, Monday, 29'th Jun 2020
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
12:45pm, Monday, 29'th Jun 2020
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan
Heron Therapeutics Target of Unusually Large Options Trading (NASDAQ:HRTX)
11:10am, Monday, 29'th Jun 2020
Heron Therapeutics Inc (NASDAQ:HRTX) was the target of some unusual options trading activity on Monday. Stock traders purchased 6,991 call options on the company. This represents an increase of approx
